2m 2m 2m 2m 2m 2m 2m
NRX PHARMA (NRXP)
NASDAQ
$4.06-$0.56 (-12.03%)
Price as of Jun 03, 2026 7:56 PM EDT- $160.1MMarket Cap
- 69.85%1-Year Change
- BiotechnologyIndustry
NRX PHARMA (NRXP)
$4.06-$0.56 (-12.03%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 1.2M N/A | 0 N/A | N/A N/A | N/A N/A | |
Cost of Revenue | 505,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 720,000 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | 13.1M N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -3.8M -39.07% | -6.2M -53.64% | -13.4M -21.47% | -17.0M -15.95% | |
Depreciation and Amortization Expense | 70,000 +1,300.00% | 5,000 0.00% | 5,000 +25.00% | 4,000 +100.00% | |
Total Operating Expenses | 17.4M -5.69% | 18.5M -33.53% | 27.8M -37.21% | 44.3M -61.71% | |
Operating Profit | -16.2M -12.31% | -18.5M -33.53% | -27.8M -37.21% | -44.3M -61.71% | |
Interest Income | 12,000 -72.73% | 44,000 -91.09% | 494,000 +98.39% | 249,000 N/A | |
Interest Expense | N/A N/A | -500,000 +316.67% | -120,000 +566.67% | -18,000 0.00% | |
Interest Income and Expense and Net | 12,000 +102.63% | -456,000 -221.93% | 374,000 +61.90% | 231,000 +1,383.33% | |
Total Nonoperating Income and Expense | -12.4M +87.17% | -6.6M +186.38% | -2.3M -150.49% | 4.6M -79.85% | |
Income before Taxes | -16.2M -35.43% | -25.1M -9.74% | -27.8M -29.98% | -39.8M -57.28% | |
Income Taxes | 0 N/A | 0 N/A | N/A N/A | 0 N/A | |
Extraordinary Items | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -28.6M +13.91% | -25.1M -16.66% | -30.1M -24.16% | -39.8M -57.28% | |
Net Income from Continuing Operations Applicable to Common | -28.6M +13.91% | -25.1M -16.66% | -30.1M -24.16% | -39.8M -88.61% | |
Basic EPS and Net Income | -1.34 -43.22% | -2.36 +490.00% | -0.40 -33.33% | -0.60 -69.70% | |
Diluted EPS and Net Income | -1.34 -43.22% | -2.36 +490.00% | -0.40 -33.33% | -0.60 -69.70% | |
Basic Weighted Average Shares | 21.4M +101.06% | 10.6M -85.95% | 75.8M +15.20% | 65.8M +40.17% | |
Diluted Weighted Average Shares | 21.4M +101.06% | 10.6M -85.95% | 75.8M +15.20% | 65.8M +40.17% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 7.8M +440.33% | 1.4M -68.60% | 4.6M -77.09% | 20.1M -27.35% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 7.8M +440.33% | 1.4M -68.60% | 4.6M -77.09% | 20.1M -27.35% | |
Total Current Assets | 8.9M +169.29% | 3.3M -52.03% | 6.9M -73.31% | 25.8M -21.15% | |
Accumulated Depreciation | 30,000 +57.89% | 19,000 N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 63,000 +530.00% | 10,000 N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | 253,000 -27.51% | 349,000 -19.03% | 431,000 +1,952.38% | 21,000 +40.00% | |
Total Assets | 13.0M +254.86% | 3.7M -50.09% | 7.3M -71.66% | 25.8M -21.12% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 0 -100.00% | 1.6M -91.45% | 18.3M +137.62% | 7.7M N/A | |
Total Current Liabilities | 28.6M +30.71% | 21.9M +14.78% | 19.0M +22.22% | 15.6M +30.71% | |
Total Long-Term Debt | 0 -100.00% | 5.0M -76.43% | 21.3M +65.35% | 12.9M N/A | |
Total Long-Term Liabilities | 199,000 -98.26% | 11.4M -4.78% | 12.0M +89,680.48% | 13,347 -99.33% | |
Total Liabilities | 28.9M +7.51% | 26.9M +41.09% | 19.0M +3.48% | 18.4M +54.38% | |
Retained Earnings | -306.9M +10.29% | -278.3M +9.93% | -253.1M +13.52% | -223.0M +21.69% | |
Total Stockholders Equity | -15.9M -31.37% | -23.2M +97.93% | -11.7M -258.36% | 7.4M -64.39% | |
Total Shares Outstanding | 31.7M +117.48% | 14.6M -82.61% | 83.9M +26.30% | 66.4M +12.98% | |
Cash Flow | |||||
Cash from Operating Activities | -14.1M +32.67% | -10.6M -50.88% | -21.7M -45.52% | -39.8M +5.44% | |
Capital Expenditures | N/A N/A | 0 -100.00% | 3,000 -70.00% | 10,000 +42.86% | |
Cash from Investing Activities | -2.8M N/A | 0 +100.00% | -3,000 -70.00% | -10,000 +42.86% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 23.3M +210.97% | 7.5M +20.71% | 6.2M -80.75% | 32.2M -49.23% | |
Financials Ratio | |||||
Gross Margin | 58.78% N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -1,324.41% N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -344.70% -24.78% | -458.25% +151.78% | -182.00% +34.02% | -135.81% -71.70% | |
Return on Equity | 146.18% +1.68% | 143.76% -89.69% | 1,394.54% +594.88% | -281.79% -65.30% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 0.31 +106.03% | 0.15 -58.22% | 0.36 -78.16% | 1.66 -39.68% | |
Cash Ratio | 0.27 +313.33% | 0.07 -72.64% | 0.24 -81.26% | 1.29 -44.42% | |
Debt-to-Equity Ratio | 0.00 +100.00% | -0.28 -91.60% | -3.37 -221.52% | 2.78 N/A | |
Debt-to-Assets Ratio | 0.00 -100.00% | 1.80 -66.71% | 5.41 +579.20% | 0.80 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow